紫元元(08223.HK)擬4000萬元購買武漢美康茂健康管理全部股權
格隆匯12月29日丨紫元元(08223.HK)公吿,於2022年12月29日,賣方葉特與買方深圳市美佳爾健康管理有限公司(公司間接全資附屬公司)訂立股權轉讓協議,據此,賣方已有條件同意出售,而買方已有條件同意購買目標公司武漢美康茂健康管理有限公司全部股權,代價為人民幣4000萬元。
目標公司主要於中國武漢從事提供產後護理服務。目標公司於中國武漢擁有一家尚未開業的月子中心,預期於2023年6月30日前開業。
中國月子中心市場規模自2010年起一直增加,並估計於2025年達約人民幣320億元,顯示該產業的前景正面,預期集團將受益於月子中心的樂觀前景。母嬰健康相關服務有剛性需求,且整體市場將繼續快速增長。集團認為收購事項為將其月子服務產業業務擴展的絕佳機會,符合集團的業務前景,並符合公司及股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.